6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

9 trials found

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000041-40-NL (EUCTR)	22/02/2022	10/11/2021	A study to investigate the effects of repeated low doses of psilocybin and ketamineon cognitive and ...	A study to investigate the effects of repeated low doses of psilocybin and ketamineon cognitive and ...	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Psilocybin INN or Proposed INN: Psilocybine Product Name: Ketamine INN or Proposed INN: K ...	Maastricht University	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	34	Phase 2	Netherlands
2	NCT04944017 (ClinicalTrials.gov)	November 23, 2021	22/6/2021	Ketamine for the Treatment of Depression in Parkinson's Disease	Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD)	Parkinson's Disease;Depression	Drug: Ketamine Infusion;Other: Placebo - Saline Infusion	Yale University	Fox (Michael J.) Foundation for Parkinson's Research	Recruiting	40 Years	80 Years	All	56	Phase 2	United States
3	NCT04912115 (ClinicalTrials.gov)	October 5, 2021	25/5/2021	Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamineto Treat Levodopa-Induced Dyski ...	A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of ...	Dyskinesias;Movement Disorders;Central Nervous System Diseases;Nervous System Diseases;Neurologic Ma ...	Drug: Ketamine;Drug: Midazolam	PharmaTher Inc.	NULL	Suspended	30 Years	85 Years	All	30	Phase 2	United States
4	NCT03858270 (ClinicalTrials.gov)	April 1, 2019	2/10/2018	Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine	Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine	Parkinson Disease	Drug: Memantine;Other: Placebo	Wayne State University	NULL	Recruiting	45 Years	85 Years	All	50	Phase 3	United States
5	NCT01785628 (ClinicalTrials.gov)	August 2010	24/6/2011	The Impact of Pharmacological and Electric Modulation of NMDAPathway on the Cognitive Flexibility an ...		Parkinson's Disease With Dementia	Dietary Supplement: Sarcosine Capsule;Dietary Supplement: Placebo Capsule	China Medical University Hospital	National Science Council, Taiwan	Completed	N/A	N/A	All	30	N/A	Taiwan
6	NCT00163085 (ClinicalTrials.gov)	May 2005	9/9/2005	The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety O ...	Parkinson's Disease	Drug: NR2B NMDA Antagonist CP-101,606 (traxoprodil)	Pfizer	NULL	Completed	30 Years	80 Years	Both	12	Phase 2	United States
7	NCT00375778 (ClinicalTrials.gov)	April 2005	12/9/2006	Parkinson's Disease Evaluated by PET and the Effect of Memantine	Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDAReceptor Ant ...	Parkinson's Disease	Drug: memantine (drug)	University of Aarhus	Lundbeck Foundation	Completed	50 Years	70 Years	Both	12	N/A	Denmark
8	NCT00001929 (ClinicalTrials.gov)	March 1999	3/11/1999	Treatment of Parkinson's Disease With Eliprodil	NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease	Movement Disorders;Parkinson Disease	Drug: Eliprodil	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	20	Phase 2	United States
9	NCT00001365 (ClinicalTrials.gov)	July 1993	3/11/1999	Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous Syst ...	NMDA Receptor Antagonist Treatment of Neurodegenerative Disease	Neurodegenerative Disease;Parkinson's Disease	Drug: dextromethorphan	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	42	Phase 2	United States

First Previous1Next Last